KIFFIK Biomedical
Expanding Practical, Non-Invasive Access to Interstitial Fluid

Researchers have long recognized the biological value of interstitial fluid (ISF), yet sampling it in a practical, repeatable way remains a challenge. Existing approaches, including suction blisters, microdialysis and microneedles, have contributed significantly to ISF research. However, they can present limitations related to invasiveness, technical complexity, collection time, sample volume and scalability, limiting the broader practical use of ISF for molecular measurement.

KIFFIK Biomedical is working to overcome this longstanding barrier by providing controlled, non-invasive and repeat access to ISF through its K-EXP™ platform. The platform is designed to give researchers and strategic partners a practical path toward repeat ISF sampling and longitudinal molecular measurement, opening opportunities to study biological processes that have previously been difficult to investigate.

“We believe access is the foundation,” says Gino Martini, PhD, Chief Scientific Officer. “Our goal has never been just to collect another biological sample. It is to create a platform that expands practical access to meaningful biological information.”

That expanded access creates opportunities across biomarker discovery, drug development, disease monitoring, precision medicine and AI-enabled healthcare.

Increasing Access to Human Biology

ISF is an information-rich biological fluid surrounding nearly every cell in the body, containing a range of biologically important molecules, including proteins, metabolites, cytokines and electrolytes, reflecting biological activity within tissues. While blood remains an essential clinical specimen, ISF offers a complementary biological perspective.

Biological signals originating within tissues may move through ISF before entering the bloodstream, where dilution, metabolism, degradation and clearance can influence the concentration and timing of biomarkers measured in blood. Viewed together, the two fluids could expand biological visibility beyond what either measurement alone can reveal.

From Biological Snapshots to Longitudinal Insight

The significance of access becomes clearer when biology is viewed as a dynamic process. Health, disease, therapy and lifestyle continuously influence biological systems, but many measurements remain episodic, providing individual snapshots rather than a view of how biology changes over time.

By improving practical access to ISF, KIFFIK is working to give researchers a more practical path toward longitudinal molecular measurement, allowing them to investigate how biological signals change over time. With access to ISF over time, researchers could examine biological changes across hours, days, weeks or months, creating a richer longitudinal view of biological processes and expanding biological visibility.

The longitudinal perspective may provide deeper insight into disease progression, therapeutic response, recovery and normal physiology. Over the longer term, Dr. Martini sees this expanding biological visibility as a way to deepen understanding of what KIFFIK describes as the ‘human operating system,’ while creating new opportunities in biomarker discovery and drug development through pharmacokinetic and pharmacodynamic studies. These applications can extend across oncology, neuroscience, metabolic and cardiac monitoring and other areas of biological monitoring.

AI adds another dimension to this opportunity. The capabilities of AI depend on the quality and depth of available data, and greater access to longitudinal molecular information could provide richer datasets for understanding how biological processes evolve over time. AI can help researchers make better sense of the biological information they can access without replacing biology.

Advancing the Future of Biomarker Access

KIFFIK is advancing the K-EXP™ platform toward clinicaldevice availability in the second half of 2026 while selectively advancing partner programs and planned clinical studies around the technology. The company's broader mission is to expand access to biological information and provide greater visibility into human biology.

That progression, from access to data to deeper biological intelligence, is central to KIFFIK's vision for moving biomarker research beyond isolated measurements toward a more dynamic understanding of how biology changes over time. KIFFIK envisions expanding not just how biology is measured, but access to the biological information that makes those measurements possible. Its work to expand biomarker access has earned it recognition as a Top Biomarker Access Technology 2026.